Cephalon Starts Phase III Modafinil Trials
Cephalon has begun Phase III clinical trials of modafinil, its treatment for narcolepsy. The sleep disorder affects around 125,000 people in the USA, according to the company.
The company says it plans to conduct the two double-blind trials, which will evaluate modafinil's efficacy in reducing the number of daytime sleep attacks, at more than 40 leading sleep research centers across the USA. After initial screening, patients will receive modafinil or placebo daily for nine weeks. Cephalon licenses modafinil from Laboratoires Lafon of France, and has exclusive rights to market the product in the USA, the UK, Republic of Ireland and Mexico.
Cephalon also says it is expecting data analysis of Phase II/III studies of its lead product Myotrophin (recombinant human insulin-like growth factor-1) for amyotrophic lateral sclerosis to be completed in the first quarter of 1995.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze